Cargando…

Erratum: Correction of Notes. Safe Re-administration of Tumor Necrosis Factor-alpha (TNFα) Inhibitors in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Who Developed Active Tuberculosis on Previous Anti-TNFα Therapy

Detalles Bibliográficos
Autores principales:	Suh, Young Sun, Kwok, Seung-ki, Ju, Ji Hyeon, Park, Kyung-Su, Park, Sung-Hwan, Yoon, Chong-Hyeon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2014
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3945147/ http://dx.doi.org/10.3346/jkms.2014.29.3.460

Ejemplares similares

Safe Re-administration of Tumor Necrosis Factor-alpha (TNFα) Inhibitors in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Who Developed Active Tuberculosis on Previous Anti-TNFα Therapy
por: Suh, Young Sun, et al.
Publicado: (2014)

Anti-TNF-α Therapy for Ankylosing Spondylitis
por: Son, Jung-Hwan, et al.
Publicado: (2010)

The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics
por: Jang, Dan-in, et al.
Publicado: (2021)

TNF-alpha antagonists for treatment of juvenile ankylosing spondylitis
por: Orbán, I, et al.
Publicado: (2011)

Association of anti-TNF-α treatment with gut microbiota of patients with ankylosing spondylitis
por: Dai, Qinghong, et al.
Publicado: (2022)

Age determines response to anti-TNFα treatment in patients with ankylosing spondylitis and is related to TNFα-producing CD8 cells
por: Schramm-Luc, Agata, et al.
Publicado: (2018)

Anti‐TNF‐α therapy alters the gut microbiota in proteoglycan‐induced ankylosing spondylitis in mice
por: Liu, Bin, et al.
Publicado: (2019)

Associations of Platelet Count with Inflammation and Response to Anti-TNF-α Therapy in Patients with Ankylosing Spondylitis
por: Qian, Hongyan, et al.
Publicado: (2020)

Treatment of ankylosing spondylitis with TNFα inhibitors does not affect serum levels of tryptophan metabolites
por: Witoszyńska-Sobkowiak, Joanna, et al.
Publicado: (2023)

Anti-TNF treatment in ankylosing spondylitis patients with chronic kidney disease: Is it effective and safe?
por: Coşkun, Belkıs Nihan, et al.
Publicado: (2022)

Golimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
por: Kay, Jonathan, et al.
Publicado: (2010)

Ankylosing Spondylitis and Rheumatoid Arthritis: Serum Levels of TNF-α and Its Soluble Receptors during the Course of Therapy with Etanercept and Infliximab
por: Schulz, Martin, et al.
Publicado: (2014)

TNF-α Induced the Enhanced Apoptosis of Mesenchymal Stem Cells in Ankylosing Spondylitis by Overexpressing TRAIL-R2
por: Liu, Zhenhua, et al.
Publicado: (2017)

Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-α inhibitors
por: Carbo, Marlies J. G., et al.
Publicado: (2018)

The relationship between blood eosinophil count and disease activity in ankylosing spondylitis patients treated with TNF-α inhibitors
por: Sargin, Gokhan, et al.
Publicado: (2018)

Rituximab Can Induce Remission in a Patient with Ankylosing Spondylitis Who Failed Anti-TNF-α Agent
por: AlDhaheri, Fahmi, et al.
Publicado: (2017)

Factors affecting drug survival of an alternative TNF inhibitor and secukinumab in patients with ankylosing spondylitis switching from the first TNF inhibitor
por: Kwon, Oh Chan, et al.
Publicado: (2021)

Tumour Necrosis Factor Alpha (TNF-α) and Oral Squamous Cell Carcinoma
por: Brierly, Gary, et al.
Publicado: (2023)

Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients
por: Ciechomska, Marzena, et al.
Publicado: (2018)

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-α therapy and other novel approaches
por: Braun, Juergen, et al.
Publicado: (2002)

Immunological Changes in Peripheral Blood of Ankylosing Spondylitis Patients during Anti-TNF-α Therapy and Their Correlations with Treatment Outcomes
por: Chen, Rongjuan, et al.
Publicado: (2021)

Influence of anti-TNF-α treatment on liver and kidney functions in patients with ankylosing spondylitis: A retrospective longitudinal study
por: Akyol, Lütfi, et al.
Publicado: (2022)

Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy
por: Ou, Jiayong, et al.
Publicado: (2021)

The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis
por: Lee, Suhwan, et al.
Publicado: (2019)

Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology
por: Czókolyová, Monika, et al.
Publicado: (2021)

Polymorphisms in Tumour Necrosis Factor Alpha (TNFα) Gene in Patients with Acute Pancreatitis
por: Özhan, Gül, et al.
Publicado: (2010)

Adverse Events of Anti-Tumor Necrosis Factor α Therapy in Ankylosing Spondylitis
por: Tong, Qiang, et al.
Publicado: (2015)

Ceramide Kinase Regulates the Production of Tumor Necrosis Factor α (TNFα) via Inhibition of TNFα-converting Enzyme
por: Lamour, Nadia F., et al.
Publicado: (2011)

A case study: consequences of ANTI-TNFα therapy and foot ulcerations. A patient with Ankylosing Spondylitis (AS) treated with Infliximab
por: Edgson, Lucy, et al.
Publicado: (2010)

Drug Retention Rates and Treatment Discontinuation among Anti-TNF-α Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice
por: Fabbroni, Marta, et al.
Publicado: (2014)

Efficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis
por: Liu, Wei, et al.
Publicado: (2016)

Genetic association between TNF-α −857 C/T polymorphism and ankylosing spondylitis susceptibility: evidence from a meta-analysis
por: Li, Yong, et al.
Publicado: (2016)

Angiotensin Converting Enzyme Activity in Anti-TNF-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients
por: Soós, Boglárka, et al.
Publicado: (2022)

A prospective clinical investigation of the effects of anti-TNF alpha therapy on exercise capacity in patients with ankylosing spondylitis
por: ÇAPKIN, Erhan, et al.
Publicado: (2019)

Tumor Necrosis Factor Alpha -308G/A Gene Polymorphisms Combined with Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio Predicts the Efficacy and Safety of Anti-TNF-α Therapy in Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Arthritis
por: Wang, Ziran, et al.
Publicado: (2022)

Imbalance between HAT and HDAC Activities in the PBMCs of Patients with Ankylosing Spondylitis or Rheumatoid Arthritis and Influence of HDAC Inhibitors on TNF Alpha Production
por: Toussirot, Eric, et al.
Publicado: (2013)

Reparative radiological changes of hip joint after TNF inhibitors in ankylosing spondylitis
por: Maatallah, Kaouther, et al.
Publicado: (2018)

Machine learning to predict early TNF inhibitor users in patients with ankylosing spondylitis
por: Lee, Seulkee, et al.
Publicado: (2020)

Glial Tumor Necrosis Factor Alpha (TNFα) Generates Metaplastic Inhibition of Spinal Learning
por: Huie, J. Russell, et al.
Publicado: (2012)

Correction: Adverse Events of Anti-Tumor Necrosis Factor α Therapy in Ankylosing Spondylitis
por: Tong, Qiang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o4n5tvd3vtspkejteieb696jl2